Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: FilerBill who wrote (585)	4/6/1997 4:09:00 PM
From: scaram(o)uche	of 6136

Crix has saved many lives, and some patients do not have much in the way of severe side-effects. Anyone with compassion should thank and respect Merck. However, your major points are way off base. Before you tell us to get educated, I'd suggest that you (1) read through the thread, (2) reference sites that are way out in front of Project Inform (such as the NATAP link cited earlier), and (3) check the labeling on crix and nelfinavir. We're here as investors. We'd be making a mistake to pay attention to your sample size (one) and a reference to outdated information. The fact is, patients are switching to nelf. It's now our goal to determine how many are switching and to estimate impact on revenues. It is great that your wife found crix in time. Merck made a bold move and scaled-up production for a difficult molecule. Hats off, without a single reservation, to Merck. Now, back to investing. ;-) Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next